PLoS ONE · 2017 · 19 citations · 37 references
MedicineCancer BiologyOncologyMetastasisTumor MicroenvironmentTumor ProgressionAngiogenesis In CancerCancer ProgressionLung MetastasisMalignant NeoplasmsTumor PromotionTumor-associated MacrophagesCancer Metastasis MechanismsCancer-associated MacrophagesDual-specificity PhosphatasesMetastasis ModelsMetastasis PromotionMetastasis-associated Macrophage RecruitmentMetastatic MechanismsTumor-associated Macrophage Recruitment
Vaccinia-H1 Related (VHR) dual-specificity phosphatase, or DUSP3, plays an important role in cell cycle regulation and its expression is altered in several human cancers. In mouse model, DUSP3 deletion prevents neo-angiogenesis and b-FGF-induced microvessel outgrowth. Considering the importance of angiogenesis in metastasis formation, our study aimed to investigate the role of DUSP3 in tumour cell dissemination. Using a Lewis Lung carcinoma (LLC) experimental metastasis model, we observed that DUSP3-/- mice developed larger lung metastases than littermate controls. DUSP3-/- bone marrow transfer to lethally irradiated DUSP3+/+ mice was sufficient to transfer the phenotype to DUSP3+/+ mice, indicating that hematopoietic cells compartment was involved in the increased tumour cell dissemination to lung tissues. Interestingly, we found a higher percentage of tumour-promoting Ly6Cint macrophages in DUSP3-/- LLC-bearing lung homogenates that was at least partially due to a better recruitment of these cells. This was confirmed by 1) the presence of higher number of the Ly6Bhi macrophages in DUSP3-/- lung homogenates and by 2) the better migration of DUSP3-/- bone marrow sorted monocytes, peritoneal macrophages and bone marrow derived macrophages (BMDMs), compared to DUSP3+/+ monocytes, macrophages and BMDMs, in response to LLC-conditioned medium. Our study demonstrates that DUSP3 phosphatase plays a key role in metastatic growth through a mechanism involving the recruitment of macrophages towards LLC-bearing lungs.
37
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M.L. Ebos, Christina R. Lee, William Cruz‐Muñoz et al. · Cancer Cell · 2009 · 1.7K citations · Full text
Medicine, Oncology, Pharmacology +16
Xiao‐Dong Zhu, Jubo Zhang, Peng–Yuan Zhuang et al. · Journal of Clinical Oncology · 2008 · 550 citations
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Sophia Frentzas, Ève Simoneau, Victoria L. Bridgeman et al. · Nature Medicine · 2016 · 436 citations
Medicine, Cancer Biology, Oncology +16